Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD-3: LY4268989 (MORF-057) in moderately to severely active ulcerative colitis
PACTR202610832430100Phase 2Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in autoimmune colitis comparing LY4268989 with Placebo (2 arms). Primary endpoint: Clinical remission at 10 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
LY4268989
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on PACTR202610832430100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202610832430100.